|
Diffuse Large B-Cell Lymphoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
The sphingosine-1-phosphate (S1P) receptor S1PR2 and its downstream adaptor Gα13 are recurrently mutationally inactivated in the germinal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL) and are silenced by the S1PR2 repressor FOXP1 in the activated B-cell like subtype of the disease.
|
31648327 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Thus, although Gα13 and RhoA activity has previously been linked to cellular transformation and metastatic potential of epithelial cancers, our findings support a tumor suppressive role for Gα13 and RhoA in Burkitt's lymphoma and DLBCL.
|
26616858 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
We identified recurrent mutations implicating a number of known and not previously identified genes and pathways in DLBCL including those related to chromatin modification (ARID1A and MEF2B), NF-κB (CARD11 and TNFAIP3), PI3 kinase (PIK3CD, PIK3R1, and MTOR), B-cell lineage (IRF8, POU2F2, and GNA13), and WNT signaling (WIF1).
|
23292937 |
2013 |
|
Diffuse Large B-Cell Lymphoma
|
0.330 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Burkitt Lymphoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Thus, although Gα13 and RhoA activity has previously been linked to cellular transformation and metastatic potential of epithelial cancers, our findings support a tumor suppressive role for Gα13 and RhoA in Burkitt's lymphoma and DLBCL.
|
26616858 |
2016 |
|
Burkitt Lymphoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
We identified 70 genes that were recurrently mutated in Burkitt lymphomas, including ID3, GNA13, RET, PIK3R1 and the SWI/SNF genes ARID1A and SMARCA4.
|
23143597 |
2012 |
|
African Burkitt's lymphoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
The genetic landscape of mutations in Burkitt lymphoma.
|
23143597 |
2012 |
|
Burkitt Leukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
The genetic landscape of mutations in Burkitt lymphoma.
|
23143597 |
2012 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
GNA13 is up-regulated in many solid tumors, including prostate cancer, where it contributes to tumor initiation, drug resistance, and metastasis.
|
31636124 |
2019 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
In this study, we demonstrate that GNA13 is upregulated in many solid tumors and impacts survival and metastases in patients.
|
29255247 |
2018 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
GNA13 has been found overexpressed in various types of cancer, which is related to tumor metastasis and progression.
|
30267476 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
This study aimed to explore the role of GNA13 in CRC and investigate the mechanism of how GNA13 promotes tumor growth.
|
30267476 |
2018 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers.
|
29255247 |
2018 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, re-expression of GNA13 (without the 3'-UTR) could partially abrogate the miR-30b-5p-induced cell proliferation and metastasis inhibition.
|
28536082 |
2017 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins.
|
27424208 |
2016 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
In our study, GNA13 was reported to be significantly up-regulated in HCC tissues, and this was correlated with several clinicopathological parameters, including tumor multiplicity (P = 0.004), TNM stage (P = 0.002), and BCLC stage (P = 0.010).
|
27883022 |
2016 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Thus, although Gα13 and RhoA activity has previously been linked to cellular transformation and metastatic potential of epithelial cancers, our findings support a tumor suppressive role for Gα13 and RhoA in Burkitt's lymphoma and DLBCL.
|
26616858 |
2016 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
LHGDN |
The data indicate that G(alpha)(13)-dependent downstream effects on RhoA activation and invasion tightly depend on cell type-specific GAP activities and that G(alpha)(13)-p190RhoGAP signaling might represent a potential target for intervention in melanoma metastasis.
|
18922893 |
2008 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
To better understand how GNA13 contributes to tumorigenesis and tumor progression, we compared the entire transcriptome of PC3 prostate cancer cells with those cells in which GNA13 expression had been silenced.
|
31636124 |
2019 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
miRNA-30d serves a critical function in colorectal cancer initiation, progression and invasion via directly targeting the GNA13 gene.
|
30651791 |
2019 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Taken together, these data indicate that GNA13 expression is a potential prognostic biomarker for tumor progression, and that interfering with GNA13-induced signaling provides a novel strategy to block TICs and drug resistance in HNSCCs.
|
29255247 |
2018 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Gα12 and Gα13, encoded by GNA12 and GNA13, respectively, are referred to as the GEP oncogene and are implicated in tumor progression.
|
26804165 |
2016 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Overall, we show that Gα13 and DDR1-Par3 differentially regulate cell-cell junctions and the actin cytoskeleton to mediate invasion in three-dimensional collagen.
|
26589794 |
2016 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of GNA13 in MCF-10a cells induced invasion, whereas knockdown of GNA13 expression in MDA-MB-231 cells inhibited invasion.
|
25889182 |
2015 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
These results place Blk upstream of the p190RhoGAP-RhoA pathway in Gα13-activated cells, overall representing an opposing signaling module during CXCL12-triggered invasion.
|
25025568 |
2014 |